Josefa García Barrado

An article published in Nature Medicine outlines the new framework for pharmacologically treating obesity and its complications established by the European Association for the Study of Obesity (EASO). The new guidelines establish semaglutide and tirzepatide as first-line treatment for this disease and most associated conditions. The team of authors, with Spanish participation, reviewed the scientific evidence on the effects of drugs on total weight loss and its complications and designed an algorithm to help medical personnel guide treatment, taking into account each patient's medical history and the action profiles of available medications.

The use of GLP-1 analog diabetes drugs-such as semaglutide, sold under the trade name Ozempic-is not linked to an increased risk of suicide, according to two studies published in JAMA Internal Medicine. The first, led by a U.S. team, analyzes data from more than 3,300 people who have participated in clinical trials. The second analyzes data from 124,517 users of these drugs in Sweden and Denmark, and compares them with an even larger group of people who used another type of diabetes medication.

A paper published today in the journal Science explores the potential of glucagon-like peptide-1 (GLP-1)-based drugs such as semaglutide to treat diseases beyond diabetes and obesity. For example, recent studies suggest that they could improve conditions ranging from depression to neurological disorders to cardiovascular and kidney disease.

The Spanish Agency of Medicines and Health Products (AEMPS) has announced that the anti-obesity drug Wegovy (semaglutide) will be available, with a doctor’s prescription, starting from May. It is the same active ingredient as Ozempic, but for patients without diabetes.